RT Journal Article
T1 Development of Betalactam-Predictor: A clinical decision tool for delabeling low-risk Betalactam Allergy patients. Initial validation in penicillin allergy
A1 Labella, Marina
A1 Nuñez, Rafael
A1 Doña, Inmaculada
A1 Rodríguez de Guzmán, Julia
A1 Moreno, Esther
A1 Garvey, Lene Heise
A1 Laguna, Jose Julio
A1 Barbaud, Annick
A1 Bonnadona, Patrizia
A1 Boel, Jonas Bredtoft
A1 Mosbech, Holger
A1 Sfriso, Giovanna
A1 Castells, Mariana
A1 Phillips, Elizabeth
A1 Torres-Jaén, María Josefa
K1 Alergia a los medicamentos
K1 Penicilina
K1 Anafilaxia
K1 Antibiogramas
AB Background: A label of betalactam (BL) allergy is estimated in around 10% of the population in their medical records. Second-line choices carry significant negative consequences, including reduced efficacy, effectiveness, and safety. This study aimed todevelop a new highly specific score constructed by selecting variables assisted by artificial intelligence to identify low-risk BL-allergic patients.Methods: In this study, derivation and validation of the BL-predictor score were performed on a retrospective cohort of 2207patients who underwent penicillin allergy testing at Málaga University Hospital (Spain). The development of the BL-predictorencompassed expert drafting and a two-step variable selection process consisting of univariate analysis and variable filtering,followed by stepwise logistic regression with resampling. To assess the efficiency, a multicentric retrospective external valida-tion was performed in 4261 patients from six populations: Salamanca and Madrid, Spain; Nashville, United States of America;Verona, Italy; Paris, France; and Copenhagen, Denmark.Results: The definitive questionnaire consisted of eight items and risk points were computed from the logistic regression modelas follows: +1 for reactions after first dose or in less than 1 h (ITEM-1), +2 for anaphylaxis (ITEM-2); +1 for previous reaction withthe culprit (ITEM-3); −1 for resolution in > 24 h (ITEM- 4); +2 for spontaneous resolution (ITEM-5); −2 for unknown symptoms
PB Wiley
YR 2026
FD 2026
LK https://hdl.handle.net/10630/45396
UL https://hdl.handle.net/10630/45396
LA eng
NO M. Labella, R. Nuñez, I. Doña, et al., “ Development of Betalactam-Predictor: A Clinical Decision Tool for Delabeling Low-Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy,” Allergy (2026): 1–13, https://doi.org/10.1111/all.70222.
NO Funding for open access charge: Universidad de Málaga / CBUA
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 3 mar 2026